MedPath

Enhancing Slow Wave Sleep in Depression

Not Applicable
Not yet recruiting
Conditions
Depression - Major Depressive Disorder
Registration Number
NCT07143838
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

The goal of this pilot study is to determine if non-invasive brain stimulation during sleep can increase deep sleep in adults with depression. It will also determine if increased deep sleep improves cognitive performance and mood ratings. Participants will be asked to wear a non-invasive device that records their brain activity and delivers transcranial electrical stimulation during sleep. Participants will also wear an actigraphy watch that measures activity levels throughout the study. In addition, participants will complete several cognitive assessments and mood and sleep questionnaires throughout the study.

Detailed Description

The purpose of this pilot study is to determine if non-invasive transcranial electrical stimulation (TES) delivered during slow-wave sleep (SWS) can enhance this stage of sleep in people with depression. Individuals with depression frequently report sleep and cognitive disturbances as symptoms associated with their depression. However, common anti-depressants often fail to improve these symptoms. A pilot study with this device showed that TES can enhance slow wave sleep in healthy individuals. This study aims to evaluate if TES will enhance deep sleep in individuals with depression as well, leading to improved sleep outcomes and potentially improving cognitive performance and mood symptoms.

This study proposes to conduct using the Sleep WISP device (Brain Electrophysiology Laboratory (BEL), Eugene, OR). Using this non-invasive device, the study will record brain activity using a technique called electroencephalography (EEG) that will be automatically scored in real-time to determine the stage of sleep. After the participant enters stable slow wave sleep, the headband will deliver the TES current (0.5-1 milliampere (mA) total) directly to the scalp through pre-set electrodes. The stimulation will be applied for 5 cycles of 5 minutes of stimulation, 1 minute of no stimulation (30 minutes total). This level and location of stimulation was previously shown as sufficient to increase SWS.

After screening and enrolling in the study, participants will have up to three nights of baseline recordings using the WISP headband to ensure successful baseline measurements are recorded. Participants will then receive TES nightly for two weeks. Participants will also wear an actigraphy watch and keep a sleep diary throughout the duration of the study. Finally, participants will complete several cognitive assessments and sleep and mood questionnaires throughout the duration of the study.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Ability to complete overnight sleep study including placement of EEG leads
  • Ability to read and understand English.
  • Moderate depression
  • Self-reported cognitive complaints
Exclusion Criteria
  • Previous adverse reaction to transcranial electrical stimulation
  • Presence of implanted devices (e.g. intracranial device, cochlear implant)
  • Presence of metal in head (e.g. surgical clip)
  • Sensitivity or allergy to silver
  • Presence of significant neurologic disease (e.g. Parkinson's disease, epilepsy/seizure disorder, severe migraine disorder)
  • History of significant head trauma
  • History of stroke or other ischemic event
  • Diagnosed with schizophrenia, bipolar disorder, substance use disorder, or presence of current suicidal ideation
  • Currently taking medications that could alter EEG or cognitive function
  • Presence of severe insomnia
  • Presence of severe, untreated sleep apnea
  • Currently pregnant
  • Planned travel outside time zone during the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Duration of Stage N3 SleepFrom baseline to week 3

Change in number of minutes of stage N3 sleep across the night

Percentage of N3 SleepFrom baseline to week 3

Change in percentage of stage N3 sleep across the night relative to total sleep time

Secondary Outcome Measures
NameTimeMethod
Word Pairs Memory TaskBaseline, week 2, week 3

Participants are presented with 44 word-pairs to learn during an encoding phase and immediately tested by presenting one word and being asked to recall the paired word. Participants are tested again in the morning in the same way - one word of the pair is presented and they are asked to recall the other. To avoid recency and priming effects, the first 4 and last 4 word pairs presented are not scored. Participants are scored on accuracy (0-36 words). A smaller decline in accuracy from the immediate recall (evening) to delayed recall phase (morning) indicates better verbal memory performance.

Choice Reaction Time (CRT)Baseline, week 2, week 3

CRT measures the time it takes for a person to respond to a stimulus when there are multiple possible responses to choose from. It is a measure of how quickly someone can process information, make a decision, and initiate a motor response. Participants are presented with 20 trials of stimuli to respond to. The test is scored on average reaction time where a longer reaction time indicates worse processing speed performance.

Digit Symbol Substitution Test (DSST)Baseline, week 2, week 3

133-item neuropsychological assessment that measures cognitive functions like processing speed, attention, and visuoperceptual skills. It involves matching symbols to numbers based on a provided key and is often used to assess cognitive impairment. The number of correct symbols within 120 seconds constitutes the score (0-133 max score) where a lower score represents greater impairment in processing speed and attention.

One-Back Working Memory TestBaseline, week 2, week 3

Cognitive test that assesses an individual's ability to hold and manipulate information in their short-term memory. The one-back working memory test is scored by assessing both accuracy and average response time. Accuracy is measured as the percentage of correct responses (hits) to target stimuli, while response time reflects the average speed at which participants identify matches. Higher accuracy and faster response times generally indicate better working memory performance. Participants are presented with 20 total trials (potential accuracy score, 0-20; potential reaction time 0-3 seconds). Both the accuracy and reaction time scores are z-scored and then combined to create a single composite score for the test.

Trail Making Test B (TMT-B)Baseline, week 2, week 3

TMT-B assesses cognitive flexibility, the ability to switch between different mental sets (in this case, numbers and letters). It also evaluates visual scanning and attention. The test taker is given a sheet of paper with 25 circles, each containing a number (1-13) or a letter (A-L). They must draw a line connecting the circles in ascending order, alternating between numbers and letters (1-A-2-B, and so on). The primary score is the time it takes to complete the task (0-300 seconds). Longer duration to complete indicates greater impairment in cognitive flexibility and attention.

Perceived Deficits Questionnaire 5 (PDQ-5)Baseline, week 2, week 3

5-item questionnaire with total score range 0-20. Higher score indicates greater perceived deficit.

Center for Epidemiologic Studies Depression Scale (CES-D)Baseline, week 2, week 3

20 items with total score range 0-60. Higher scores indicate greater severity of depressive symptoms.

Patient Health Questionnaire (PHQ-9)Baseline, week 2, week 3

9 items with total score range 0-27. Higher scores indicate greater severity of depressive symptoms.

Trial Locations

Locations (1)

Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
Ruth Benca, MD PhD
Contact
336-716-2911
ruth.benca@advocatehealth.org
Caitlin Carroll, PhD
Contact
336-716-2440
caitlin.carroll@advocatehealth.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.